One cut homeobox 2 (ONECUT2 or OC-2) is a newly discovered transcription factor. Aberrant expression of OC-2 is closely related to cell proliferation, migration, invasion, and angiogenesis. In this study, we found that OC-2 expression was upreg- istry showed that the densities of microvessels stained with CD31, the expression of OC-2 and VEGFA were significantly decreased in tumors. These data indicated that OC-2 was an upstream regulator of VEGFA and silencing OC-2 could inhibit ovarian cancer angiogenesis and tumor growth.
cell precursors, which can be derived from adjacent vessels or from incorporation of bone marrow-derived endothelial precursor cells. 9 However, tumor neovascularization, consisting only of vascular endothelial cells, has been challenged by vasculogenic mimicry (VM). 10 Tang et al 11 indicated that vasculogenic mimicry was an alternative way to supply adequate blood for ovarian cancer. Research on tumor angiogenesis had progressed slowly until important discoveries of the major molecular drivers of tumor angiogenesis: the VEGF family and its homologous receptors. 12 In addition to VEGF, other important pathways also contribute to tumor angiogenesis. 8 One cut homeobox 2 (ONECUT2 or OC-2) was first reported by Patrick et al 13 as the second member of the ONECUT family, whose prototype was hepatocyte nuclear factor-6, characterized by the presence of a single cut domain and by a specific homeodomain. The expression status of OC-2 could be used for bladder cancer epigenetic analysis and the results had high sensitivity and specificity. 14 As an angiogenic and EMT-related transcription factor, OC-2 plays a key role in tumor cell invasion, metastasis, EMT, and oncogenesis. 15 , 16 Sun et al 15 reported that microRNA-429 inhibited the activation of EMT and regulated the expression of EMT-related markers by targeting OC-2. Zhang et al 16 introduced the idea that OC-2 was upregulated in hepatocellular carcinoma and partially acted as a tumor promoter through the Akt/Erk signaling pathway. However, the relationship between OC-2 expression level and ovarian cancer development is still not clear.
In order to study the relationship between OC-2 expression and the development of ovarian cancer, we used siRNA to silence the expression of the OC-2 gene in ovarian cancer cells. The results
showed that the ability of cell proliferation, migration, invasion, and endothelial cell formation had decreased significantly. In addition, a mouse xenograft model revealed that silencing OC-2 remarkably inhibited tumor growth and angiogenesis. These OC-2 silencing studies could provide a new direction for gene therapy for ovarian cancer angiogenesis.
| MATERIALS AND METHODS

| Cell culture
Ovarian cancer cell lines (CAOV3, COV-362, COV-504, EFO-27, ES-2, OV-90, SKOV3, and TOV-21G) were obtained from ATCC and grown in DMEM with 10% FBS. Cells were serum-starved and cultured in DMEM with 0.5% FBS overnight. Human umbilical vein endothelial cells were cultured in RPMI-1640 medium with 10%
FBS. All these cells were cultured in an incubator with 95% humidity and 5% CO 2 at 37°C.
| Small interfering RNA vector construction and transfection
Two siRNAs (siRNA#1 and siRNA#2) targeting OC-2 and an siRNA (siRNA-VEGFA) targeting VEGFA were designed according to Yu et al. 17 The siRNAs were inserted into pGPU6-GFP-Neo vector (Genepharma, Suzhou, China) to construct pGPU6-GFP-Neo-siRNA#1
(siRNA#2) and pGPU6-GFP-Neo-siRNA-VEGFA, respectively. A scrambled siRNA was used as negative control. The siRNAs sequences are listed in Tables 1,2 
| Cell proliferation assay
The cell viability was measured by CCK-8 assay (Dojindo Molecular Technologies 
| Western blot analysis
The ovarian cancer cells were washed with cold PBS and lysed in RIPA buffer (Beyotime, Suzhou, China). The lysates were centrifuged at 12 000 g for 8 minutes at 4°C and the total protein in the supernatant were quantified by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). Total proteins were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, USA).
The membranes were blocked with 5% non-fat milk for 1 hour at 37°C and incubated with rabbit anti-human ONECUT2 polyclonal antibody (1:1000; Abcam), rabbit anti-VEGFA polyclonal antibody 
| Real-time quantitative PCR analysis
The total RNAs were extracted from cells with TRIzol reagent (Invitrogen, China). The RT reactions were carried out using a SYBR green-containing PCR kit (Qingke, China). The primers for real-time PCR were used to detect the mRNA expression of hypoxia-inducible factor-1a (HIF-1a), VEGFC, hepatocyte growth factor (HGF), fibroblast growth factor 2 (FGF2), Snai1, Snai2, transforming growth factor-b1 (TGF-b1), and Twist1. The sequences of real-time PCR primers are listed in Table 3 . The primers were synthesized and purified by Beijing Qingke Biotechnology. All real-time PCR procedures were carried out on the CFX96 detection system (Bio-Rad, USA). The cell migration rate of each group was calculated. 19 The cell migration inhibition rate = (1 À OC2-siRNA group migration distance/siRNA NC group migration distance) 9 100%.
| Migration and invasion assays
Migration and invasion assays of ovarian cancer cells were evaluated using an 8-lm Transwell chamber (BD Biosciences) according to the instructions. SKOV3 and COV-504 cells (2 9 10 4 cells) were transfected with OC2-siRNAs (siRNA#1, siRNA#2, and siRNA NC) and then transferred to the upper chamber of the Transwell in 200 lL DEME basic medium for 24 hours. In the lower chamber, 600 lL DEME medium with 10% FBS was added as a chemoattractant.
For Matrigel invasion assays, Transwells were coated with 60 lL . 19 At the end of 21 days, nude mice were euthanized and tumors were stripped for immunohistochemistry assays.
| Immunohistochemistry
Immunohistochemistry was carried out as previously described. 19, 20 The tumor tissue samples of ovarian cancer patients were provided 
T A B L E 3 Primer sequences of real-time PCR
Gene
Forward primer (5
by The Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). For human ovarian cancer tissue, the primary antibody was rabbit anti-human ONECUT2 polyclonal antibody (1:500 Technology), and rabbit anti-mouse ONECUT2 polyclonal antibody
(1:500 dilution, ab28466; Abcam). The biotinylated HRP-conjugated secondary antibody was a goat anti-rabbit IgG.
| Statistical analysis
Statistical analyses were carried out by one-way ANOVA followed by the least significant difference test using the statistical software and P < .01 (**) were considered statistically significant.
| Ethics
The hospital ethics committee approved the study protocol, and all patients provided gave consent for the utilization of their tissue samples in this study.
| RESULTS
| Overexpression of OC-2 in some ovarian cancer cells and tissues
Previous studies have indicated that OC-2 was expressed highly in liver cancer and colon cancer. 15, 16 To explore the expression and sig- with siRNA#1 (siRNA#2) decreased by 70%-75% (66%-72%) compared to the NC group (P < .01) ( Figure 3A) .
The invasion rate of COV-504 and SKOV3 cells transfected with siRNA#1 (siRNA#2) were reduced by 71%-76% (69%-74%) (P < .01) ( Figure 3B ). We further investigated the effect of OC-2 silencing on the migration of ovarian cancer cells through wound healing assays ( Figure 3C ). The results showed that the migration inhibition rate of COV-504 and SKOV3 cells transfected with siRNA#1 (siRNA#2)
reached 83%-86% (86%-89%) (P < .01). These data suggest that OC-2 silencing could significantly inhibit the migration and invasion of ovarian carcinoma cells.
| Silencing OC-2 expression in ovarian cancer cells inhibits endothelial angiogenesis
Anti-angiogenic therapy is used as a primary treatment for ovarian cancer. 21 To test the role of OC-2 in ovarian cancer cells stimulating angiogenesis, the conditioned media were collected from the COV-504 and SKOV3 cells transfected with OC2-siRNAs, and stimulated
HUVECs on Matrigel-coated plates ( Figure 4A ,B). The conditioned ONECUT-2 is a transcription factor, we speculated that OC-2 could regulate the release of angiogenic factors in the ovarian tumor microenvironment to stimulate angiogenesis. Our preliminary data indicated that OC-2 was associated with VEGFA, the most important molecule involved in angiogenesis. Therefore, the expression of VEGFA was detected by Western blot after OC-2 silencing on COV-504 and SKOV3 cells. The results showed that OC-2 silencing significantly inhibited the expression of VEGFA (Figure 5A ). In addition, COV-504 and SKOV3 cells transfected with siRNA-VEGFA or pAAV-VEGFA were collected and lysed for Western blot analysis after 48 hours. The results showed that the expression of OC-2 was not affected after silencing or overexpression of VEGFA ( Figure 5B,C) .
F I G U R E 3 Silencing ONECUT-2 (OC-2) inhibits migration and invasion of ovarian cancer cells. A, Inhibitory effect of OC2-siRNAs on the migration of COV-504 and SKOV3 cells. (a,c) Migration ability of COV-504 and SKOV3 cells transfected with OC2-siRNAs for
F I G U R E 5
Silencing ONECUT-2 (OC-2) inhibits the expression of angiogenesis-related factors. A, Vascular endothelial growth factor A (VEGFA) expression in COV-504 and SKOV3 cells after transfection with OC2-siRNAs for 48 h. B, OC-2 expression was detected after overexpression of VEGFA. C, VEGFA expression in COV-504 and SKOV3 cells was detected after transfection with siRNA-VEGFA for 48 h. D, Hepatocyte growth factor (HGF) and hypoxia-inducible factor-1a (HIF-1a) mRNA expression were detected by real-time PCR. E, mRNA expression of VEGFC and fibroblast growth factor 2 (FGF2) were detected by real-time PCR. Data were represented as the means AE SD. *P < .05, **P < .01. ACTB, b-actin; NC, scrambled siRNA 
| Silencing of OC-2 inhibits phosphorylation of AKT, ERK1/2, and EMT
The pathway of AKT/ERK has been verified to correlate with tumor growth and angiogenesis. [22] [23] [24] ONECUT-2 decreased the proliferation rate of SKOV3 and COV-504 cells, and showed a time-dependent inhibition of cell growth ( Figure 2D ,E). To further assess whether OC-2 affected the downstream signaling pathway involved in cell proliferation and angiogenesis, p-Akt and p-Erk were investigated by Western blot assay. The results showed that silencing OC-2 could inhibit the phosphorylation of Akt and Erk ( Figure 6A ).
ONECUT-2 is a transcription factor associated with EMT, and Ncadherin and E-cadherin are important markers of EMT development. 15, 25 As a feature of aggressive tumors, EMT is characterized by reduced E-cadherin and increased N-cadherin expression, contributing to a stroma-oriented cellular adhesion profile with increased tumor cell motility and invasive properties. [26] [27] [28] To explore the relationship between OC-2 and EMT-related markers, N-cadherin and E-cadherin expression were detected after silencing OC-2 by Western blot, and the mRNA expression of Snai1, Snai2, TGF-b1, and Twist1 were detected after silencing OC-2 by real-time PCR.
Our results showed that E-cadherin expression increased and Ncadherin decreased after OC-2 silencing on SKOV3 and COV-504 cells (Figure 6Ba-e) . In addition, the real-time PCR results showed that the expression levels of TGF-b1 in COV-504 and SKOV3 cells transfected with siRNA#1 reduced by approximately 56% and 48%, respectively (P < .05). The Snai2 expression levels were downregulated by approximately 45% and 40%, respectively (P < .05). The Twist1 expression levels were decreased by nearly 51% and 53%, respectively (P < .05). In contrast, the Snai1 expression levels declined by 25% and 20%, respectively, but the results did not reach a significant level (Figure 6Bf ).
These results implied that OC-2 might play a role through the Akt/Erk signaling pathway to promote ovarian cancer cell proliferation and activate EMT to improve migration and invasion in ovarian cancer cells.
| Silencing OC-2 inhibits ovarian tumor growth and angiogenesis
In order to investigate OC-2 silencing on COV-504 cells growth and angiogenesis in vivo, a xenograft tumor model of ovarian cancer was established in BALB/c nude mice. COV-504 cells transfected with siRNA#1 and siRNA NC were injected into nude mice for 21 days; the mice were euthanized and the tumors stripped ( Figure 7A ). The OC-2 silenced group showed a significant inhibition in tumor growth (P < .05) from the day 7, whereas the siRNA NC group showed a continuous increase ( Figure 7B ). In accordance with this observation, the average weight of tumors in the OC-2 silenced group was significantly reduced compared to the control group (P < .01) ( Figure 7C ).
The stripped tumors were sectioned for immunohistochemistry staining with CD31, OC-2, VEGFA, and HIF-1a ( Figure 7D ). The immunohistochemistry results showed that the number of microvessels decreased by approximately 72% in the silenced group (P < .01) (Figure 7E) . The OC-2 expression reduced by 77%-81% (P < .01). The expression of VEGFA decreased by 78%-83% (P < .01) and the HIF1a expression decreased by 72%-78% (P < .01) ( Figure 7F ).
These data suggest that OC-2 could be an important regulator of angiogenesis and tumor growth in ovarian cancer.
| DISCUSSION
Previous studies regarding OC-2 focused on the regulatory role of the ONECUT family in the differentiation and growth of liver tissues F I G U R E 7 ONECUT-2 (OC-2) silencing inhibits tumor growth and angiogenesis in an ovarian cancer xenograft nude mice model. A, COV-504 ovarian cancer cells transfected with siRNA#1/scrambled siRNA (siRNA NC) were injected into the right shoulder of BALB/c nude mice (n = 10). Mice were euthanized and the tumors were excised after 21 d. B, Growth curves of tumors. C, Quantitative analysis of tumor weight. D, Paraffin sections of tumors were stained with OC-2, CD31, VEGFA, and HIF-1a antibody. The positive rates were statistically analyzed. E, Tumors were stained with CD31 antibody. Microvessel densities were quantified. The numbers of blood vessels at five high-power fields (9200) per section were counted. F, Positive expression rates of vascular endothelial growth factor A (VEGFA), OC-2, and hypoxia-inducible factor-1a (HIF-1a) in tumors. Data were represented as the means AE SD. *P < .05, **P < .01
and visual cells, as well as the specific diagnosis of bladder cancer. [29] [30] [31] It was reported that OC-2 existed in the nucleus and its expression was significantly increased in colorectal carcinoma relative to paracancerous normal tissues. 15 Zhang et al 16 found that OC-2 was significantly upregulated in tumor tissues compared with non-tumor tissues and might play an oncogenic role in hepatocellular carcinoma development. Sun et al 15 showed that transcript factor OC-2 was involved in the EMT, migration, and invasion of colorectal carcinoma cells. However, the role of OC-2 on tumor development in ovarian cancer patients has not been reported.
In this study, we found that OC-2 expression was elevated in some malignant ovarian cancer tissues compared to normal ovarian tissue. Similarly, the high expression of OC-2 in COV-504 and Zhang et al 16 found that Akt/Erk signaling was activated when microRNA-9 targeted OC-2. The Akt/Erk signaling pathway is closely related to cell proliferation, migration, and angiogenesis. 32 We tried to investigate its effect on ovarian cancer cell proliferation by silencing the OC-2 gene. The results showed that the proliferation rate of SKOV3 and COV-504 cells was significantly reduced and the phosphorylation levels of AKT/ERK were also inhibited. Therefore, OC-2 might regulate the proliferation of ovarian cancer cells through the AKT/ERK signaling pathway.
Epithelial-mesenchymal transition is an essential and important step in tumor cell invasion and distant metastasis. 33 ONECUT-2 could promote EMT, one of the well-defined processes during tumor invasion and distant metastasis. 15, 16 Our Western blot results
showed that E-cadherin expression was increased and N-cadherin expression was decreased after OC-2 silencing. The real-time PCR results showed a significant decrease in mRNA expression of TGFb1, Snai2, and Twist1 relative to the control group. Aomatsu et al 34 found that TGF-b downregulated E-cadherin and upregulated N-cadherin in the human corneal epithelial cell line and it could induce sustained upregulation of Snai1 and Snai2 through both Smad and non-Smad pathways (human corneal epithelial cell line). Olmeda et al 35 found that interference of endogenous Snai2 in mouse carcinoma cells affected EMT and cooperates with Snai1 silencing in decreased invasiveness. Moreover, Snai2 is also an essential mediator of Twist1-induced EMT and metastasis. 36 Therefore, we hypothesized that the expression of TGF-b1 is significantly inhibited after silencing the OC-2 gene and then suppresses the expression of nuclear transcription factors Twist1, Snail2, and Snai1 by a complex regulatory network. Twist1 was also significantly inhibited by Snai2-mediated EMT, and this series of changes in these transcription factors significantly reduced the inhibitory effect on the E-cadherin promoter, resulting in a significant decrease in migration and invasion of ovarian cancer cells. 36, 37 These results indicated that high expression of OC-2 in ovarian cancer cells could stimulate cell migration and invasion and break through the epithelial basement membrane. This is particularly relevant to the strong metastatic capacity of highly differentiated malignant ovarian cancer cells. 38 Subsequently, we used siRNA to silence OC-2 expression to investigate its effect on angiogenesis in vitro and in vivo. In vitro, the conditioned medium after silencing OC-2 in ovarian cancer cells significantly inhibited the tube formation numbers of HUVECs. Western blot assay showed that VEGFA expression was decreased after OC-2 silencing, but silencing and overexpression of VEGFA did not significantly affect OC-2 expression. These results indicated that OC-2
was an upstream regulator of VEGFA. In addition, we found that HIF1a expression was significantly reduced after silencing OC-2 by realtime PCR and the mouse tumor immunohistochemistry experiments.
The mRNA expression levels of VEGFC, HGF, and FGF2 also decreased in varying degrees after silencing OC-2 expression in ovarian cancer cells by RT-PCR. Hypoxia stimulates new blood vessel formation in coronary artery disease, tumor angiogenesis, and diabetic neovascularization. [39] [40] [41] Hypoxia-inducible factor-1a increase of VEGF expression is due to both transcriptional activation and increased mRNA stability. 42 Tacchini et al 43 Our results provided proof of targeting OC-2 for anti-angiogenesis therapy in ovarian cancer; OC-2 might be a marker of ovarian cancer-specific detection.
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